ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, March  12, 2020  (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) seeks to correct statements made by an unaffiliated third-party, Merkel Media Group on behalf of its unnamed client, implying unsupported health claims about Tru Niagen and COVID-19. There are no published human clinical studies evaluating the effects of Tru Niagen® supplementation with the Coronavirus. As such, no health claims can be made related to COVID-19 at this time.

ChromaDex Corrects Statements Made by an Unaffiliated Third Party Regarding its Product and COVID-19

ChromaDex Corp. (CDXC) CEO Rob Fried on Q4 2019 Results - Earnings Call Transcript

Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models Preclinical study demonstrates the effects of short-term nicotinamide riboside (NR) supplementation in preventing hearing loss in animal models

New Niagen® Nicotinamide Riboside (NR) Study Deepens Understanding of NAD Decline and Hearing Loss in Animal Model

Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service Tru Niagen® to launch in Persona’s customized vitamin and nutritional supplement delivery service

ChromaDex Partners with Personalized Nutrition Company, Persona Nutrition, Expanding Global Partnership with Nestlé Health Science

ChromaDex launches new research tools for the CBD industry with line of reference standards ChromaDex launches new research tools for the CBD industry with line of reference standards

ChromaDex Launches New Line of High Purity Cannabinoid (CBD) Reference Standards Available for Research and Analytical Testing Worldwide

ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity ChromaDex receives authorizations to sell its patented, NAD+ boosting nicotinamide riboside chloride in the European Union and in Australia with market exclusivity

ChromaDex Achieves New Regulatory Milestones in the European Union & Australia

Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3 Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3

First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension

LOS ANGELES, Dec.  16, 2019  (GLOBE NEWSWIRE) --  ChromaDex Corp.  (NASDAQ:CDXC) announced today that Nutritional Outlook® , a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen® (nicotinamide riboside).  The state of the science surrounding Niagen will be presented during the ChromaDex Scientific Advisory Board (SAB) annual meeting taking place Dec. 16-17 in Los Angeles, CA.

ChromaDex Wins Nutritional Outlook’s 2019 “Best of Industry” Ingredient Supplier Award for Niagen®

Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners Tru Niagen® Pro 500 to be distributed exclusively through licensed healthcare practitioners

ChromaDex Launches Tru Niagen® Pro 500, the Largest Serving of Patented Nicotinamide Riboside Available Worldwide

ChromaDex and Matakana Health commit to continued sales growth in Oceania, following approval from Australian regulatory body ChromaDex and Matakana Health commit to continued sales growth in Oceania, following approval from Australian regulatory body

ChromaDex and Matakana Announce Expanded Retail Partnership in Australia & New Zealand

ChromaDex advances in regulatory process for its patented nicotinamide riboside chloride (NR) ingredient in Australia; receives market exclusivity for two years ChromaDex advances in regulatory process for its patented nicotinamide riboside chloride (NR) ingredient in Australia; receives market exclusivity for two years

ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA)

ChromaDex achieves milestone for the launch of nicotinamide riboside in Europe ChromaDex achieves milestone for the launch of nicotinamide riboside in Europe

European Commission Votes in Favor on Nicotinamide Riboside Chloride as a Novel Food

ChromaDex Corporation's (CDXC) CEO Rob Fried on Q3 2019 Results - Earnings Call Transcript

Tru Niagen® Recognized as MoneyBack Members’ Most Favourite Brand at Health, Wellness & Beauty Awards 2019 of Watsons Hong Kong Tru Niagen® Recognized as MoneyBack Members’ Most Favourite Brand at Health, Wellness & Beauty Awards 2019 of Watsons Hong Kong

Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty Members

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

LOS ANGELES, Oct.  17, 2019  (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the  results of a preclinical study conducted by Nestlé were published last month in the journal   Nature Communications  , a peer-reviewed open access scientific journal published by the Nature Publishing Group. The study investigated the impact on the liver when its cells lose the ability to use the nutrient nicotinamide riboside (NR). The preclinical study concluded that the tissue’s natural ability to utilize NR is important for maintaining resilience during periods of metabolic stress such as a high-fat diet. It is also the first study to show the physiological consequences that arise when cells lose the ability to use NR.

New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors

LOS ANGELES, Oct.  11, 2019  (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) issued the following statement.

ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation

LOS ANGELES, Oct.  07, 2019  (GLOBE NEWSWIRE) -- Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive factors in milk and the effect of the supplements on brain development in animals.

Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents

LOS ANGELES, Sept.  26, 2019  (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5th Annual B. Riley FBR Consumer and Media Conference at the Sofitel Hotel in New York, NY.

ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference

Ventas

Age is the most significant factor contributing to wealth.

Taking Advantage Of Getting Old

ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2019 Results - Earnings Call Transcript

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

ChromaDex Corp (NASDAQ: CDXC) announced the results of its latest clinical study were published in the journal Scientific Reports.

ChromaDex Shares Nicotinamide Riboside Study Results

ChromaDex Corporation's (CDXC) CEO Rob Fried on Q1 2019 Results - Earnings Call Transcript

News for ChromaDex Stock (CDXC)